Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBITDA MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) Net Margin (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed Net Margin for 1 consecutive years, with 729144.44% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Net Margin changed N/A year-over-year to 729144.44%, compared with a TTM value of 729144.44% through Sep 2025, up 72584586.0%, and an annual FY2022 reading of 11174.75%, down 627691.0% over the prior year.
  • Net Margin was 729144.44% for Q4 2024 at Summit Therapeutics, up from 2021.89% in the prior quarter.
  • Across five years, Net Margin topped out at 729144.44% in Q4 2024 and bottomed at 1458.19% in Q1 2024.